European report gets nasty about NICE and the QALY
This article was originally published in Scrip
The QALY-based approach used by NICE, the health technology appraisal institute for England and Wales, is heavily flawed and should not be adopted by other European member states, warns a European Commission-sponsored project. The four main assumptions underpinning the QALY about how patients value additional life gain and different health states are invalid, according to the survey. "Everything it is based upon is wrong," said Ariel Beresniak, leader of the project which reported its results at a symposium in Brussels on 25 January.
You may also be interested in...
Pharmaceutical industry groups say the European Commission’s Pharmaceutical Strategy Roadmap lacks detail on delivering a faster regulatory process and encouraging competitiveness.
The Australian Therapeutic Goods Administration is consulting on a draft standard for data matrix codes on the labels of certain medicines.
The European Medicines Agency received more requests for scientific advice in 2019 than it did in 2018. Meanwhile, requests for advice in other areas has fallen.